Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
In the Phase III 4WHIM trial, Xolremdi showed a 60% reduction in annualized infection rate compared to placebo
Prev Med 5(Suppl 1):S79S82
LIPOSOMAL TECHNOLOGY
You can now earn CE credit for the Live San Diego Conference through the following accrediting bodies: AMA PRA Category 1 Credits ACPE ANCC CDR
Results Search Results A total of 17 studies were identified by literature search [one with two eligible contrasts ( Pooled Effect-Size Between-studies heterogeneity was not significant for VR ( I 2 = 12.8%, Cochran's Q = 24.14, p = 0.19) and CVR ( I 2 = 0%, Cochran's Q = 14.33, p = 0.76) estimates, but as expected, for SMDH there was a significant between-studies heterogeneity ( I 2 = 47.4%, Cochran's Q = 37.15, p = 0.008)
2023), although studies in other conditions suggest that it may play a role in oxidative stress (Zhang et al
US$ 23.85
US$ 27.91
US$ 28.70
US$ 24.36
